AAM
HRMY icon

Azzad Asset Management’s Harmony Biosciences HRMY Stock Holding History

Azzad Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,607
Closed -$282K – 312
2023
Q3 		$282K Buy
8,607
+211
+3% +$7.33K 0.04% 288
2023
Q2 		$295K Buy
8,396
+174
+2% +$6.01K 0.04% 299
2023
Q1 		$268K Buy
+8,222
New +$374K 0.04% 296

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Azzad Asset Management's HRMY Position: Q4 2023 in Review

Azzad Asset Management sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 8,607 shares — an estimated $282K sold.

Azzad Asset Management first reported a position in HRMY in Q1 2023 and held it in 3 quarters. The position peaked at $295K in Q2 2023. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

  • Azzad Asset Management reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
  • Azzad Asset Management sold 8,607 Harmony Biosciences shares in Q4 2023, an estimated $282K.
  • Azzad Asset Management first reported a position in Harmony Biosciences in Q1 2023 and held it in 3 quarters.
  • Azzad Asset Management's Harmony Biosciences position peaked at $295K in Q2 2023.
  • 221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on Azzad Asset Management's 13F filing for Q4 2023, filed 1 Apr 2024.